 |
||||||
|
|
||||||
 |
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
|
|
|
||||
|
|
|
|
|
||||
 |
|||||||
The fine chemical/pharmaceutical industry has matured and downsized, with technological advances emanating from smaller, equally downsized R&D organizations. The result is that many of today's recent technological advances have created only incremental benefit for companies, such as a change in an intermediate that provides fractional cost betterment. Yet, despite its maturity, the industry also creates from time to time real breakthrough advances, such as chiral drug NCE's, combinatorial NCE development and more recently, single-site catalysis that have begun to affect most fine chemicals businesses for the foreseeable future. Understanding the business impact of these breakthroughs and developing the strategies to do so are the goals of The Catalyst Group.
|
|
|||
|
|
|||
|
|
|||